Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol
- PMID:1436470
- DOI: 10.1016/0306-4522(92)90099-n
Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol
Abstract
It has been suggested that not only mesostriatal but also mesolimbic pathways are involved in the degeneration of dopaminergic neurons in Parkinson's disease. Using quantitative ligand autoradiography we have investigated dopamine transporter sites in basal ganglia of patients affected by Huntington's chorea, Parkinson's disease and progressive supranuclear palsy. [3H]Mazindol, a ligand for catecholamine uptake, was used in the presence of desipramine to block the binding to norepinephrine uptake sites. Schizophrenic cases were entered in the study to take into account the effects of neuroleptics, commonly administered also to Huntington's disease patients, on dopamine uptake sites. In control cases high densities of [3H]mazindol binding sites were found in the caudate nucleus, putamen and nucleus accumbens, whereas very low densities were present in substantia nigra and ventral tegmental area. In Huntington's chorea the density of [3H]mazindol binding sites was slightly decreased in the caudate nucleus, an area severely affected by the neurodegenerative process. In schizophrenic patients the density of dopamine uptake sites in the basal ganglia was slightly reduced, mainly in the middle third of putamen. Both Parkinson's disease and progressive supranuclear palsy populations were characterized by a marked loss of [3H]mazindol binding sites in the neostriatum (about 75%) and in the nucleus accumbens (about 65%). These results suggest that in Parkinson's disease and progressive supranuclear palsy severe decreases of dopamine uptake sites occur not only in the mesostriatal pathway but also in the mesolimbic tract.
Similar articles
- Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM.Chinaglia G, et al.Neuroscience. 1993 Jun;54(3):691-9. doi: 10.1016/0306-4522(93)90240-g.Neuroscience. 1993.PMID:8332256
- Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia.Chinaglia G, Probst A, Palacios JM.Chinaglia G, et al.Neuroscience. 1990;39(2):351-60. doi: 10.1016/0306-4522(90)90273-7.Neuroscience. 1990.PMID:1965015
- Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK.Piggott MA, et al.Brain. 1999 Aug;122 ( Pt 8):1449-68. doi: 10.1093/brain/122.8.1449.Brain. 1999.PMID:10430831
- Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.Hornykiewicz O, Shannak K.Hornykiewicz O, et al.J Neural Transm Suppl. 1994;42:219-27. doi: 10.1007/978-3-7091-6641-3_17.J Neural Transm Suppl. 1994.PMID:7964689Review.
- Dopamine receptors and transporters in Parkinson's disease and schizophrenia.Seeman P, Niznik HB.Seeman P, et al.FASEB J. 1990 Jul;4(10):2737-44. doi: 10.1096/fasebj.4.10.2197154.FASEB J. 1990.PMID:2197154Review.
Cited by
- Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.Stehouwer JS, Goodman MM.Stehouwer JS, et al.PET Clin. 2009 Jan;4(1):101-28. doi: 10.1016/j.cpet.2009.05.006.PET Clin. 2009.PMID:20216936Free PMC article.
- Alterations in dopamine and serotonin uptake systems in the striatum of the weaver mutant mouse.Stotz EH, Palacios JM, Landwehrmeyer B, Norton J, Ghetti B, Simon JR, Triarhou LC.Stotz EH, et al.J Neural Transm Gen Sect. 1994;97(1):51-64. doi: 10.1007/BF01277962.J Neural Transm Gen Sect. 1994.PMID:7888149
- Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance.Parker KL, Alberico SL, Miller AD, Narayanan NS.Parker KL, et al.Neuroscience. 2013;255:246-54. doi: 10.1016/j.neuroscience.2013.09.057. Epub 2013 Oct 10.Neuroscience. 2013.PMID:24120554Free PMC article.
- Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS.Tessitore A, et al.J Neurosci. 2002 Oct 15;22(20):9099-103. doi: 10.1523/JNEUROSCI.22-20-09099.2002.J Neurosci. 2002.PMID:12388617Free PMC article.Clinical Trial.
- Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.Stehouwer JS, Daniel LM, Chen P, Voll RJ, Williams L, Plott SJ, Votaw JR, Owens MJ, Howell L, Goodman MM.Stehouwer JS, et al.J Med Chem. 2010 Aug 12;53(15):5549-57. doi: 10.1021/jm100269c.J Med Chem. 2010.PMID:20597489Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical